<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01225731</url>
  </required_header>
  <id_info>
    <org_study_id>P05495</org_study_id>
    <secondary_id>2009-017272-24</secondary_id>
    <secondary_id>MK-3222-003</secondary_id>
    <nct_id>NCT01225731</nct_id>
  </id_info>
  <brief_title>A Study to Determine the Optimal Dose of Tildrakizumab (SCH 900222/MK-3222) for the Treatment of Moderate-to-severe Chronic Plaque Psoriasis (P05495) (MK-3222-003)</brief_title>
  <official_title>Randomized, Double-Blinded, Placebo-Controlled, Parallel-Design, Dose-Range Finding Study of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis (Study P05495)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a response-driven study of tildrakuzumab for the treatment of moderate to severe
      chronic plaque psoriasis. The primary study hypothesis is that one or more doses of
      tildrakizumab will be superior to placebo for the treatment of psoriasis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Each participant will be enrolled in the trial for approximately 72-76 weeks. Each
      participant will receive assigned treatment at Weeks 0 and 4 in Part I. At Week 16, the
      dosage of treatment the patient is assigned to may be adjusted based on the Psoriasis Area
      and Severity Index (PASI) 75 response (responder vs non-responder). Participants will receive
      study medication once every 12 weeks during Part 2 (Weeks 16 to 52); no participants will
      receive placebo in Part 2. Part 3 is an observational period and each subject will continue
      to be monitored on a monthly basis through Week 72. Subjects will not receive any study
      medication during Part 3.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With a Psoriasis Area and Severity Index (PASI)75 Response at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>The PASI score measures the severity and extent of psoriasis. Using a scale of 0=none to 4= very severe, each body region (head, trunk, arms, and legs) is rated for redness, thickness, and scaling of the largest psoriatic area in that region producing a Lesion Score. The percentage of the area affected by disease is then estimated, ranging from 0 = no lesions to 6 = 90-100% of the region is covered providing an Area Score. Then, the Lesion Score and Area Score for each region are multiplied, producing 4 subtotals. The 4 region subtotals are multiplied by a standardized percentage of body surface area for that region (head = 0.1, trunk = 0.3, arms=0.2, and legs = 0.4); these four region calculations are added to provide the final PASI score, ranging from 0 = no disease to 72 = maximal disease). PASI 75 response was defined as &gt;=75% improvement in PASI score when compared to the baseline score.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Experiencing Adverse Events</measure>
    <time_frame>Up to 72 weeks</time_frame>
    <description>An adverse event is any unfavorable and unintended change in the structure, function, or chemistry of the body whether or not considered related to the study treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Particpants Discontinuing Study Treatment Due to Adverse Events</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>An adverse event is any unfavorable and unintended change in the structure, function, or chemistry of the body whether or not considered related to the study treatment. Participants may be discontinued from study drug due to adverse events, but remain on the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a PASI 75 Response at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>The PASI score measures the severity and extent of psoriasis. Using a scale of 0=none to 4= very severe, each body region (head, trunk, arms, and legs) is rated for redness, thickness, and scaling of the largest psoriatic area in that region producing a Lesion Score. The percentage of the area affected by disease is then estimated, ranging from 0 = no lesions to 6 = 90-100% of the region is covered providing an Area Score. Then, the Lesion Score and Area Score for each region are multiplied, producing 4 subtotals. The 4 region subtotals are multiplied by a standardized percentage of body surface area for that region (head = 0.1, trunk = 0.3, arms=0.2, and legs = 0.4); these four region calculations are added to provide the final PASI score, ranging from 0 = no disease to 72 = maximal disease). PASI 75 response was defined as &gt;=75% improvement in PASI score when compared to the baseline score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Physician's Global Assessment (PGA) of &quot;Cleared&quot; or &quot;Minimal&quot; at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>The PGA is used to determine the overall severity of a subject's psoriasis lesions at a given time point. Overall lesions will be graded for induration, erythema, and scaling on a scale from 0 to 5. The sum of the 3 scales will be divided by 3 to obtain the PGA score. PGA is assessed as: 0= Cleared, except for residual discoloration. 1= Minimal, majority of lesions have individual scores that average . 2 =Mild, majority of lesions have individual scores that average 2. 3= Modreate, majority of lesions have individual scores that average 3. 4= Marked, majority of lesions have individual scores that average 4. 5= Severe, majority of lesions have individual scores that average 5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With PASI 90 Response at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>The PASI score measures the severity and extent of psoriasis. Using a scale of 0=none to 4= very severe, each body region (head, trunk, arms, and legs) is rated for redness, thickness, and scaling of the largest psoriatic area in that region producing a Lesion Score. The percentage of the area affected by disease is then estimated, ranging from 0 = no lesions to 6 = 90-100% of the region is covered providing an Area Score. Then, the Lesion Score and Area Score for each region are multiplied, producing 4 subtotals. The 4 region subtotals are multiplied by a standardized percentage of body surface area for that region (head = 0.1, trunk = 0.3, arms=0.2, and legs = 0.4); these four region calculations are added to provide the final PASI score, ranging from 0 = no disease to 72 = maximal disease). PASI 90 response was defined as &gt;=90 % improvement in PASI score when compared to the baseline score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With PASI 100 Response at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>The PASI score measures the severity and extent of psoriasis. Using a scale of 0=none to 4= very severe, each body region (head, trunk, arms, and legs) is rated for redness, thickness, and scaling of the largest psoriatic area in that region producing a Lesion Score. The percentage of the area affected by disease is then estimated, ranging from 0 = no lesions to 6 = 90-100% of the region is covered providing an Area Score. Then, the Lesion Score and Area Score for each region are multiplied, producing 4 subtotals. The 4 region subtotals are multiplied by a standardized percentage of body surface area for that region (head = 0.1, trunk = 0.3, arms=0.2, and legs = 0.4); these four region calculations are added to provide the final PASI score, ranging from 0 = no disease to 72 = maximal disease). PASI 100 response was defined as 100 % improvement in PASI score when compared to the baseline score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PASI 75 Response Rate by Time</measure>
    <time_frame>Up to 16 Weeks</time_frame>
    <description>The PASI score measures the severity and extent of psoriasis. Using a scale of 0=none to 4= very severe, each body region (head, trunk, arms, and legs) is rated for redness, thickness, and scaling of the largest psoriatic area in that region producing a Lesion Score. The percentage of the area affected by disease is then estimated, ranging from 0 = no lesions to 6 = 90-100% of the region is covered providing an Area Score. Then, the Lesion Score and Area Score for each region are multiplied, producing 4 subtotals. The 4 region subtotals are multiplied by a standardized percentage of body surface area for that region (head = 0.1, trunk = 0.3, arms=0.2, and legs = 0.4); these four region calculations are added to provide the final PASI score, ranging from 0 = no disease to 72 = maximal disease).PASI 75 response was defined as &gt;=75% improvement in PASI score when compared to the baseline score at Week 2, 4, 6, 8, 12, or 16.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in PASI Score at Weeks 12 and 16</measure>
    <time_frame>Baseline and Weeks 12 and 16</time_frame>
    <description>The PASI score measures the severity and extent of psoriasis. Using a scale of 0=none to 4= very severe, each body region (head, trunk, arms, and legs) is rated for redness, thickness, and scaling of the largest psoriatic area in that region producing a Lesion Score. The percentage of the area affected by disease is then estimated, ranging from 0 = no lesions to 6 = 90-100% of the region is covered providing an Area Score. Then, the Lesion Score and Area Score for each region are multiplied, producing 4 subtotals. The 4 region subtotals are multiplied by a standardized percentage of body surface area for that region (head = 0.1, trunk = 0.3, arms=0.2, and legs = 0.4); these four region calculations are added to provide the final PASI score, ranging from 0 = no disease to 72 = maximal disease).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With PASI 50 Response at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>The PASI score measures the severity and extent of psoriasis. Using a scale of 0=none to 4= very severe, each body region (head, trunk, arms, and legs) is rated for redness, thickness, and scaling of the largest psoriatic area in that region producing a Lesion Score. The percentage of the area affected by disease is then estimated, ranging from 0 = no lesions to 6 = 90-100% of the region is covered providing an Area Score. Then, the Lesion Score and Area Score for each region are multiplied, producing 4 subtotals. The 4 region subtotals are multiplied by a standardized percentage of body surface area for that region (head = 0.1, trunk = 0.3, arms=0.2, and legs = 0.4); these four region calculations are added to provide the final PASI score, ranging from 0 = no disease to 72 = maximal disease). PASI 50 response was defined as &gt;=50 % improvement in PASI score when compared to the baseline score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>The DLQI is a 10-item questionnaire that measures how much participant skin problems have affected their life. Responses range from 0=Not at all to 3=Very much. The DLQI is broken down into 6 subscales: Symptoms and feelings (range 0-6), Daily activities (range 0-6), Leisure (range 0-6), Work and school (range 0-3), Personal relationships (range 0-6), and Treatment (range 0-3). DLQI subscales were summed to yield the DLQI total score, which could range from 0 to 30. For both DLQI subscales and DLQI total score, a higher score indicated a greater negative impact on life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving DLQI Score of 0 or 1 at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>The DLQI is a 10-item questionnaire that measures how much participant skin problems have affected their life. Responses range from 0=Not at all to 3=Very much. The DLQI is broken down into 6 subscales: Symptoms and feelings (range 0-6), Daily activities (range 0-6), Leisure (range 0-6), Work and school (range 0-3), Personal relationships (range 0-6), and Treatment (range 0-3). DLQI subscales were summed to yield the DLQI total score, which could range from 0 to 30. For both DLQI subscales and DLQI total score, a higher score indicated a greater negative impact on life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving a &gt;=5 Point Reduction in DLQI at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>The DLQI is a 10-item questionnaire that measures how much participant skin problems have affected their life. Responses range from 0=Not at all to 3=Very much. The DLQI is broken down into 6 subscales: Symptoms and feelings (range 0-6), Daily activities (range 0-6), Leisure (range 0-6), Work and school (range 0-3), Personal relationships (range 0-6), and Treatment (range 0-3). DLQI subscales were summed to yield the DLQI total score, which could range from 0 to 30. For both DLQI subscales and DLQI total score, a higher score indicated a greater negative impact on life.</description>
  </secondary_outcome>
  <number_of_arms>14</number_of_arms>
  <enrollment type="Actual">355</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Part 1: Tildrakizumab 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive tildrakizumab 5 mg, subcutaneously (SC) at Weeks 0 and 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Tildrakizumab 25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive tildrakizumab 25 mg, SC, at Weeks 0 and 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Tildrakizumab 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive tildrakizumab 100 mg, SC, at Weeks 0 and 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Tildrakizumab 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive tildrakizumab 200 mg, SC, at Weeks 0 and 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receive placebo, SC, at Weeks 0 and 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Tildrakizumab 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive tildrakizumab 5 mg, SC, every 12 weeks for up to 36 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Tildrakizumab 25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive tildrakizumab 25 mg, SC, every 12 weeks for up to 36 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Tildrakizumab 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive tildrakizumab 100 mg, SC, every 12 weeks for up to 36 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Tildrakizumab 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive tildrakizumab 200 mg, SC, every 12 weeks for up to 36 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3: Tildrakizumab 5 mg Follow-up</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants are followed for up to 20 weeks after the last dose of study drug.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3: Tildrakizumab 25 mg Follow-up</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants are followed for up to 20 weeks after the last dose of study drug.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3: Tildrakizumab 100 mg Follow-up</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants are followed for up to 20 weeks after the last dose of study drug.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3: Tildrakizumab 200 mg Follow-up</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants are followed for up to 20 weeks after the last dose of study drug.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3: Placebo Follow-up</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants are followed for up to 20 weeks after the last dose of study drug.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>tildrakizumab</intervention_name>
    <description>SC administration of tildrakizumab at assigned dose</description>
    <arm_group_label>Part 1: Tildrakizumab 5 mg</arm_group_label>
    <arm_group_label>Part 1: Tildrakizumab 25 mg</arm_group_label>
    <arm_group_label>Part 1: Tildrakizumab 100 mg</arm_group_label>
    <arm_group_label>Part 1: Tildrakizumab 200 mg</arm_group_label>
    <arm_group_label>Part 2: Tildrakizumab 5 mg</arm_group_label>
    <arm_group_label>Part 2: Tildrakizumab 25 mg</arm_group_label>
    <arm_group_label>Part 2: Tildrakizumab 100 mg</arm_group_label>
    <arm_group_label>Part 2: Tildrakizumab 200 mg</arm_group_label>
    <other_name>SCH 900222</other_name>
    <other_name>MK-3222</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>SC administration of Placebo</description>
    <arm_group_label>Part 1: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult participants (≥18 years of age) with a diagnosis of moderate-to-severe chronic
             plaque psoriasis (defined by ≥10% body surface area [BSA] involvement, &quot;moderate&quot; or
             greater score on the Physician's Global Assessment [PGA] scale, and PASI score ≥12 at
             Baseline)

          -  Participants must have a diagnosis of predominantly plaque psoriasis for ≥6 months (as
             determined by interview and confirmation of diagnosis through physical examination by
             investigator) and be considered candidates for phototherapy or systemic therapy.
             Participants with psoriatic arthritis may be included in the study

        Exclusion Criteria:

          -  Nonplaque forms of psoriasis specifically erythrodermic psoriasis, predominantly
             pustular psoriasis, medication-induced or medication-exacerbated psoriasis, or new
             onset guttate psoriasis

          -  Participants who will require oral or injectable corticosteroids during the trial

          -  Presence of any infection requiring treatment with systemic antibiotics within 2 weeks
             prior to Screening, or serious infection (eg, pneumonia, cellulitis, bone or joint
             infections) requiring hospitalization or treatment with intravenous antibiotics within
             8 weeks prior to Screening

          -  Participants with evidence of active or untreated latent tuberculosis (TB) according
             to Screening criteria specified in the protocol. (Prophylactic treatment for latent TB
             as per local guidelines must be initiated at least 4 weeks prior to treatment with
             study medication)

          -  Previous exposure to any agents targeting interleukin-12 (IL-12) and/or Interleukin-23
             (IL-23)

          -  Participants with prior exposure to two or more tumor necrosis factor (TNF)
             antagonists with discontinuation due to lack of efficacy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Norway</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Papp K, Thaçi D, Reich K, Riedl E, Langley RG, Krueger JG, Gottlieb AB, Nakagawa H, Bowman EP, Mehta A, Li Q, Zhou Y, Shames R. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. Br J Dermatol. 2015 Oct;173(4):930-9. doi: 10.1111/bjd.13932. Epub 2015 Oct 15. Erratum in: Br J Dermatol. 2016 Jun;174(6):1426.</citation>
    <PMID>26042589</PMID>
  </results_reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 7, 2010</study_first_submitted>
  <study_first_submitted_qc>October 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2010</study_first_posted>
  <results_first_submitted>March 18, 2015</results_first_submitted>
  <results_first_submitted_qc>March 18, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 30, 2015</results_first_posted>
  <last_update_submitted>July 25, 2017</last_update_submitted>
  <last_update_submitted_qc>July 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/study.html?id=P05495&amp;kw=P05495&amp;tab=access</doc_url>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Part 1: Tildrakizumab 5 mg</title>
          <description>Participants receive tildrakizumab 5 mg, subcutaneously (SC) at Weeks 0 and 4</description>
        </group>
        <group group_id="P2">
          <title>Part 1: Tildrakizumab 25 mg</title>
          <description>Participants receive tildrakizumab 25 mg, SC, at Weeks 0 and 4</description>
        </group>
        <group group_id="P3">
          <title>Part 1: Tildrakizumab 100 mg</title>
          <description>Participants receive tildrakizumab 100 mg, SC, at Weeks 0 and 4</description>
        </group>
        <group group_id="P4">
          <title>Part 1: Tildrakizumab 200 mg</title>
          <description>Participants receive tildrakizumab 200 mg, SC, at Weeks 0 and 4</description>
        </group>
        <group group_id="P5">
          <title>Part 1: Placebo</title>
          <description>Participants receive placebo, SC, at Weeks 0 and 4</description>
        </group>
        <group group_id="P6">
          <title>Part 2: Tildrakizumab 5 mg</title>
          <description>Participants receive tildrakizumab 5 mg, SC, every 12 weeks for up to 36 weeks</description>
        </group>
        <group group_id="P7">
          <title>Part 2: Tildrakizumab 25 mg</title>
          <description>Participants receive tildrakizumab 25 mg, SC, every 12 weeks for up to 36 weeks</description>
        </group>
        <group group_id="P8">
          <title>Part 2: Tildrakizumab 100 mg</title>
          <description>Participants receive tildrakizumab 100 mg, SC, every 12 weeks for up to 36 weeks</description>
        </group>
        <group group_id="P9">
          <title>Part 2: Tildrakizumab 200 mg</title>
          <description>Participants receive tildrakizumab 200 mg, SC, every 12 weeks for up to 36 weeks</description>
        </group>
        <group group_id="P10">
          <title>Part 3: Tildrakizumab 5 mg Follow-up</title>
          <description>Participants are followed for up to 20 weeks after the last dose of study drug.</description>
        </group>
        <group group_id="P11">
          <title>Part 3: Tildrakizumab 25 mg Follow-up</title>
          <description>Participants are followed for up to 20 weeks after the last dose of study drug.</description>
        </group>
        <group group_id="P12">
          <title>Part 3: Tildrakizumab 100 mg Follow-up</title>
          <description>Participants are followed for up to 20 weeks after the last dose of study drug.</description>
        </group>
        <group group_id="P13">
          <title>Part 3: Tildrakizumab 200 mg Follow-up</title>
          <description>Participants are followed for up to 20 weeks after the last dose of study drug.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="92"/>
                <participants group_id="P3" count="89"/>
                <participants group_id="P4" count="86"/>
                <participants group_id="P5" count="46"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="87"/>
                <participants group_id="P3" count="88"/>
                <participants group_id="P4" count="84"/>
                <participants group_id="P5" count="40"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Did not meet eligibility criteria</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">Participants could progress into Part 2</participants>
                <participants group_id="P2" count="0">Participants could progress into Part 2</participants>
                <participants group_id="P3" count="0">Participants could progress into Part 2</participants>
                <participants group_id="P4" count="0">Participants could progress into Part 2</participants>
                <participants group_id="P5" count="0">Participants could progress into Part 2; no placebo was given in Part 2</participants>
                <participants group_id="P6" count="13">Participants were reassigned based on PASI score at Week 16</participants>
                <participants group_id="P7" count="94">Participants were reassigned based on PASI score at Week 16</participants>
                <participants group_id="P8" count="153">Participants were reassigned based on PASI score at Week 16</participants>
                <participants group_id="P9" count="79">Participants were reassigned based on PASI score at Week 16</participants>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="10"/>
                <participants group_id="P7" count="86"/>
                <participants group_id="P8" count="128"/>
                <participants group_id="P9" count="68"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="8"/>
                <participants group_id="P8" count="25"/>
                <participants group_id="P9" count="11"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="4"/>
                <participants group_id="P8" count="4"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="12"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="4"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0">Participants could enter the follow-up period</participants>
                <participants group_id="P7" count="0">Participants could enter the follow-up period</participants>
                <participants group_id="P8" count="0">Participants could enter the follow-up period</participants>
                <participants group_id="P9" count="0">Participants could enter the follow-up period</participants>
                <participants group_id="P10" count="10">Not all participants entered follow-up</participants>
                <participants group_id="P11" count="86">Not all participants entered follow-up</participants>
                <participants group_id="P12" count="126">Not all participants entered follow-up</participants>
                <participants group_id="P13" count="67">Not all participants entered follow-up</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="10"/>
                <participants group_id="P11" count="80"/>
                <participants group_id="P12" count="116"/>
                <participants group_id="P13" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="6"/>
                <participants group_id="P12" count="10"/>
                <participants group_id="P13" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="2"/>
                <participants group_id="P13" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="4"/>
                <participants group_id="P12" count="6"/>
                <participants group_id="P13" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Part 1: Tildrakizumab 5 mg</title>
          <description>Participants receive tildrakizumab 5 mg, subcutaneously (SC) at Weeks 0 and 4</description>
        </group>
        <group group_id="B2">
          <title>Part 1: Tildrakizumab 25 mg</title>
          <description>Participants receive tildrakizumab 25 mg, SC, at Weeks 0 and 4</description>
        </group>
        <group group_id="B3">
          <title>Part 1: Tildrakizumab 100 mg</title>
          <description>Participants receive tildrakizumab 100 mg, SC, at Weeks 0 and 4</description>
        </group>
        <group group_id="B4">
          <title>Part 1: Tildrakizumab 200 mg</title>
          <description>Participants receive tildrakizumab 200 mg, SC, at Weeks 0 and 4</description>
        </group>
        <group group_id="B5">
          <title>Part 1: Placebo</title>
          <description>Participants receive placebo, SC, at Weeks 0 and 4</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="42"/>
            <count group_id="B2" value="92"/>
            <count group_id="B3" value="89"/>
            <count group_id="B4" value="86"/>
            <count group_id="B5" value="46"/>
            <count group_id="B6" value="355"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.2" spread="12.9"/>
                    <measurement group_id="B2" value="46.3" spread="13.7"/>
                    <measurement group_id="B3" value="45.5" spread="12.8"/>
                    <measurement group_id="B4" value="43.2" spread="12.6"/>
                    <measurement group_id="B5" value="45.9" spread="11.7"/>
                    <measurement group_id="B6" value="44.9" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="85"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="76"/>
                    <measurement group_id="B4" value="65"/>
                    <measurement group_id="B5" value="38"/>
                    <measurement group_id="B6" value="270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With a Psoriasis Area and Severity Index (PASI)75 Response at Week 16</title>
        <description>The PASI score measures the severity and extent of psoriasis. Using a scale of 0=none to 4= very severe, each body region (head, trunk, arms, and legs) is rated for redness, thickness, and scaling of the largest psoriatic area in that region producing a Lesion Score. The percentage of the area affected by disease is then estimated, ranging from 0 = no lesions to 6 = 90-100% of the region is covered providing an Area Score. Then, the Lesion Score and Area Score for each region are multiplied, producing 4 subtotals. The 4 region subtotals are multiplied by a standardized percentage of body surface area for that region (head = 0.1, trunk = 0.3, arms=0.2, and legs = 0.4); these four region calculations are added to provide the final PASI score, ranging from 0 = no disease to 72 = maximal disease). PASI 75 response was defined as &gt;=75% improvement in PASI score when compared to the baseline score.</description>
        <time_frame>Week 16</time_frame>
        <population>The Full Analysis Set (FAS), all randomized participants who received &gt;=1 dose of study drug and had a baseline and &gt;=1 post-treatment efficacy measurement. The last non-missing post-baseline PASI score was carried forward (LOCF) unless the participant discontinued drug due to lack of efficacy, loss of response, or use of prohibited medications.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Tildrakizumab 5 mg</title>
            <description>Participants receive tildrakizumab 5 mg, subcutaneously (SC) at Weeks 0 and 4</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Tildrakizumab 25 mg</title>
            <description>Participants receive tildrakizumab 25 mg, SC, at Weeks 0 and 4</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Tildrakizumab 100 mg</title>
            <description>Participants receive tildrakizumab 100 mg, SC, at Weeks 0 and 4</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Tildrakizumab 200 mg</title>
            <description>Participants receive tildrakizumab 200 mg, SC, at Weeks 0 and 4</description>
          </group>
          <group group_id="O5">
            <title>Part 1: Placebo</title>
            <description>Participants receive placebo, SC, at Weeks 0 and 4</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Psoriasis Area and Severity Index (PASI)75 Response at Week 16</title>
          <description>The PASI score measures the severity and extent of psoriasis. Using a scale of 0=none to 4= very severe, each body region (head, trunk, arms, and legs) is rated for redness, thickness, and scaling of the largest psoriatic area in that region producing a Lesion Score. The percentage of the area affected by disease is then estimated, ranging from 0 = no lesions to 6 = 90-100% of the region is covered providing an Area Score. Then, the Lesion Score and Area Score for each region are multiplied, producing 4 subtotals. The 4 region subtotals are multiplied by a standardized percentage of body surface area for that region (head = 0.1, trunk = 0.3, arms=0.2, and legs = 0.4); these four region calculations are added to provide the final PASI score, ranging from 0 = no disease to 72 = maximal disease). PASI 75 response was defined as &gt;=75% improvement in PASI score when compared to the baseline score.</description>
          <population>The Full Analysis Set (FAS), all randomized participants who received &gt;=1 dose of study drug and had a baseline and &gt;=1 post-treatment efficacy measurement. The last non-missing post-baseline PASI score was carried forward (LOCF) unless the participant discontinued drug due to lack of efficacy, loss of response, or use of prohibited medications.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="89"/>
                <count group_id="O4" value="86"/>
                <count group_id="O5" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.33"/>
                    <measurement group_id="O2" value="64.44"/>
                    <measurement group_id="O3" value="66.29"/>
                    <measurement group_id="O4" value="74.42"/>
                    <measurement group_id="O5" value="4.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by baseline weight (≤90 kg or &gt;90 kg) and prior use of biologics for psoriasis (Yes/No).</method_desc>
            <param_type>% Difference in Response Rate</param_type>
            <param_value>28.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>13.41</ci_lower_limit>
            <ci_upper_limit>44.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by baseline weight (≤90 kg or &gt;90 kg) and prior use of biologics for psoriasis (Yes/No).</method_desc>
            <param_type>% Difference in Response Rate</param_type>
            <param_value>60.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>48.42</ci_lower_limit>
            <ci_upper_limit>71.58</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by baseline weight (≤90 kg or &gt;90 kg) and prior use of biologics for psoriasis (Yes/No).</method_desc>
            <param_type>% Difference in Response Rate</param_type>
            <param_value>61.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>50.33</ci_lower_limit>
            <ci_upper_limit>73.37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by baseline weight (≤90 kg or &gt;90 kg) and prior use of biologics for psoriasis (Yes/No).</method_desc>
            <param_type>% Difference in Response Rate</param_type>
            <param_value>69.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>58.96</ci_lower_limit>
            <ci_upper_limit>80.99</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a PASI 75 Response at Week 12</title>
        <description>The PASI score measures the severity and extent of psoriasis. Using a scale of 0=none to 4= very severe, each body region (head, trunk, arms, and legs) is rated for redness, thickness, and scaling of the largest psoriatic area in that region producing a Lesion Score. The percentage of the area affected by disease is then estimated, ranging from 0 = no lesions to 6 = 90-100% of the region is covered providing an Area Score. Then, the Lesion Score and Area Score for each region are multiplied, producing 4 subtotals. The 4 region subtotals are multiplied by a standardized percentage of body surface area for that region (head = 0.1, trunk = 0.3, arms=0.2, and legs = 0.4); these four region calculations are added to provide the final PASI score, ranging from 0 = no disease to 72 = maximal disease). PASI 75 response was defined as &gt;=75% improvement in PASI score when compared to the baseline score.</description>
        <time_frame>Week 12</time_frame>
        <population>The FAS, all randomized participants who received &gt;=1 dose of study drug and had a baseline and &gt;=1 post-treatment efficacy measurement. The last non-missing post-baseline PASI score was carried forward (LOCF) unless the participant discontinued drug due to lack of efficacy, loss of response, or use of prohibited medications.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Tildrakizumab 5 mg</title>
            <description>Participants receive tildrakizumab 5 mg, subcutaneously (SC) at Weeks 0 and 4</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Tildrakizumab 25 mg</title>
            <description>Participants receive tildrakizumab 25 mg, SC, at Weeks 0 and 4</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Tildrakizumab 100 mg</title>
            <description>Participants receive tildrakizumab 100 mg, SC, at Weeks 0 and 4</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Tildrakizumab 200 mg</title>
            <description>Participants receive tildrakizumab 200 mg, SC, at Weeks 0 and 4</description>
          </group>
          <group group_id="O5">
            <title>Part 1: Placebo</title>
            <description>Participants receive placebo, SC, at Weeks 0 and 4</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a PASI 75 Response at Week 12</title>
          <description>The PASI score measures the severity and extent of psoriasis. Using a scale of 0=none to 4= very severe, each body region (head, trunk, arms, and legs) is rated for redness, thickness, and scaling of the largest psoriatic area in that region producing a Lesion Score. The percentage of the area affected by disease is then estimated, ranging from 0 = no lesions to 6 = 90-100% of the region is covered providing an Area Score. Then, the Lesion Score and Area Score for each region are multiplied, producing 4 subtotals. The 4 region subtotals are multiplied by a standardized percentage of body surface area for that region (head = 0.1, trunk = 0.3, arms=0.2, and legs = 0.4); these four region calculations are added to provide the final PASI score, ranging from 0 = no disease to 72 = maximal disease). PASI 75 response was defined as &gt;=75% improvement in PASI score when compared to the baseline score.</description>
          <population>The FAS, all randomized participants who received &gt;=1 dose of study drug and had a baseline and &gt;=1 post-treatment efficacy measurement. The last non-missing post-baseline PASI score was carried forward (LOCF) unless the participant discontinued drug due to lack of efficacy, loss of response, or use of prohibited medications.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="89"/>
                <count group_id="O4" value="86"/>
                <count group_id="O5" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.81"/>
                    <measurement group_id="O2" value="58.89"/>
                    <measurement group_id="O3" value="60.67"/>
                    <measurement group_id="O4" value="72.09"/>
                    <measurement group_id="O5" value="4.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.009</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by baseline weight (≤90 kg or &gt;90 kg) and prior use of biologics for psoriasis (Yes/No).</method_desc>
            <param_type>% Difference in Response Rate</param_type>
            <param_value>19.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.15</ci_lower_limit>
            <ci_upper_limit>33.58</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by baseline weight (≤90 kg or &gt;90 kg) and prior use of biologics for psoriasis (Yes/No).</method_desc>
            <param_type>% Difference in Response Rate</param_type>
            <param_value>54.44</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>42.63</ci_lower_limit>
            <ci_upper_limit>66.26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by baseline weight (≤90 kg or &gt;90 kg) and prior use of biologics for psoriasis (Yes/No).</method_desc>
            <param_type>% Difference in Response Rate</param_type>
            <param_value>56.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>44.43</ci_lower_limit>
            <ci_upper_limit>68.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by baseline weight (≤90 kg or &gt;90 kg) and prior use of biologics for psoriasis (Yes/No).</method_desc>
            <param_type>% Difference in Response Rate</param_type>
            <param_value>67.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>56.42</ci_lower_limit>
            <ci_upper_limit>78.88</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Physician’s Global Assessment (PGA) of “Cleared” or “Minimal” at Week 16</title>
        <description>The PGA is used to determine the overall severity of a subject’s psoriasis lesions at a given time point. Overall lesions will be graded for induration, erythema, and scaling on a scale from 0 to 5. The sum of the 3 scales will be divided by 3 to obtain the PGA score. PGA is assessed as: 0= Cleared, except for residual discoloration. 1= Minimal, majority of lesions have individual scores that average . 2 =Mild, majority of lesions have individual scores that average 2. 3= Modreate, majority of lesions have individual scores that average 3. 4= Marked, majority of lesions have individual scores that average 4. 5= Severe, majority of lesions have individual scores that average 5.</description>
        <time_frame>Week 16</time_frame>
        <population>The Full Analysis Set (FAS), all randomized participants who received &gt;=1 dose of study drug and had a baseline and &gt;=1 post-treatment efficacy measurement. The last non-missing post-baseline PGA value was carried forward (LOCF) unless the participant discontinued drug due to lack of efficacy, loss of response, or use of prohibited medications.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Tildrakizumab 5 mg</title>
            <description>Participants receive tildrakizumab 5 mg, subcutaneously (SC) at Weeks 0 and 4</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Tildrakizumab 25 mg</title>
            <description>Participants receive tildrakizumab 25 mg, SC, at Weeks 0 and 4</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Tildrakizumab 100 mg</title>
            <description>Participants receive tildrakizumab 100 mg, SC, at Weeks 0 and 4</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Tildrakizumab 200 mg</title>
            <description>Participants receive tildrakizumab 200 mg, SC, at Weeks 0 and 4</description>
          </group>
          <group group_id="O5">
            <title>Part 1: Placebo</title>
            <description>Participants receive placebo, SC, at Weeks 0 and 4</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Physician’s Global Assessment (PGA) of “Cleared” or “Minimal” at Week 16</title>
          <description>The PGA is used to determine the overall severity of a subject’s psoriasis lesions at a given time point. Overall lesions will be graded for induration, erythema, and scaling on a scale from 0 to 5. The sum of the 3 scales will be divided by 3 to obtain the PGA score. PGA is assessed as: 0= Cleared, except for residual discoloration. 1= Minimal, majority of lesions have individual scores that average . 2 =Mild, majority of lesions have individual scores that average 2. 3= Modreate, majority of lesions have individual scores that average 3. 4= Marked, majority of lesions have individual scores that average 4. 5= Severe, majority of lesions have individual scores that average 5.</description>
          <population>The Full Analysis Set (FAS), all randomized participants who received &gt;=1 dose of study drug and had a baseline and &gt;=1 post-treatment efficacy measurement. The last non-missing post-baseline PGA value was carried forward (LOCF) unless the participant discontinued drug due to lack of efficacy, loss of response, or use of prohibited medications.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="89"/>
                <count group_id="O4" value="86"/>
                <count group_id="O5" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.33"/>
                    <measurement group_id="O2" value="57.78"/>
                    <measurement group_id="O3" value="61.80"/>
                    <measurement group_id="O4" value="74.42"/>
                    <measurement group_id="O5" value="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by baseline weight (≤90 kg or &gt;90 kg) and prior use of biologics for psoriasis (Yes/No).</method_desc>
            <param_type>% Difference in Response Rate</param_type>
            <param_value>31.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>16.22</ci_lower_limit>
            <ci_upper_limit>46.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by baseline weight (≤90 kg or &gt;90 kg) and prior use of biologics for psoriasis (Yes/No).</method_desc>
            <param_type>% Difference in Response Rate</param_type>
            <param_value>55.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>44.48</ci_lower_limit>
            <ci_upper_limit>66.63</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by baseline weight (≤90 kg or &gt;90 kg) and prior use of biologics for psoriasis (Yes/No).</method_desc>
            <param_type>% Difference in Response Rate</param_type>
            <param_value>59.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>48.60</ci_lower_limit>
            <ci_upper_limit>70.55</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by baseline weight (≤90 kg or &gt;90 kg) and prior use of biologics for psoriasis (Yes/No).</method_desc>
            <param_type>% Difference in Response Rate</param_type>
            <param_value>72.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>62.02</ci_lower_limit>
            <ci_upper_limit>82.37</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With PASI 90 Response at Week 16</title>
        <description>The PASI score measures the severity and extent of psoriasis. Using a scale of 0=none to 4= very severe, each body region (head, trunk, arms, and legs) is rated for redness, thickness, and scaling of the largest psoriatic area in that region producing a Lesion Score. The percentage of the area affected by disease is then estimated, ranging from 0 = no lesions to 6 = 90-100% of the region is covered providing an Area Score. Then, the Lesion Score and Area Score for each region are multiplied, producing 4 subtotals. The 4 region subtotals are multiplied by a standardized percentage of body surface area for that region (head = 0.1, trunk = 0.3, arms=0.2, and legs = 0.4); these four region calculations are added to provide the final PASI score, ranging from 0 = no disease to 72 = maximal disease). PASI 90 response was defined as &gt;=90 % improvement in PASI score when compared to the baseline score.</description>
        <time_frame>Week 16</time_frame>
        <population>The FAS, all randomized participants who received &gt;=1 dose of study drug and had a baseline and &gt;=1 post-treatment efficacy measurement, and data for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Tildrakizumab 5 mg</title>
            <description>Participants receive tildrakizumab 5 mg, subcutaneously (SC) at Weeks 0 and 4</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Tildrakizumab 25 mg</title>
            <description>Participants receive tildrakizumab 25 mg, SC, at Weeks 0 and 4</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Tildrakizumab 100 mg</title>
            <description>Participants receive tildrakizumab 100 mg, SC, at Weeks 0 and 4</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Tildrakizumab 200 mg</title>
            <description>Participants receive tildrakizumab 200 mg, SC, at Weeks 0 and 4</description>
          </group>
          <group group_id="O5">
            <title>Part 1: Placebo</title>
            <description>Participants receive placebo, SC, at Weeks 0 and 4</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With PASI 90 Response at Week 16</title>
          <description>The PASI score measures the severity and extent of psoriasis. Using a scale of 0=none to 4= very severe, each body region (head, trunk, arms, and legs) is rated for redness, thickness, and scaling of the largest psoriatic area in that region producing a Lesion Score. The percentage of the area affected by disease is then estimated, ranging from 0 = no lesions to 6 = 90-100% of the region is covered providing an Area Score. Then, the Lesion Score and Area Score for each region are multiplied, producing 4 subtotals. The 4 region subtotals are multiplied by a standardized percentage of body surface area for that region (head = 0.1, trunk = 0.3, arms=0.2, and legs = 0.4); these four region calculations are added to provide the final PASI score, ranging from 0 = no disease to 72 = maximal disease). PASI 90 response was defined as &gt;=90 % improvement in PASI score when compared to the baseline score.</description>
          <population>The FAS, all randomized participants who received &gt;=1 dose of study drug and had a baseline and &gt;=1 post-treatment efficacy measurement, and data for this endpoint.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="88"/>
                <count group_id="O4" value="84"/>
                <count group_id="O5" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.50"/>
                    <measurement group_id="O2" value="25.29"/>
                    <measurement group_id="O3" value="38.64"/>
                    <measurement group_id="O4" value="52.38"/>
                    <measurement group_id="O5" value="2.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With PASI 100 Response at Week 16</title>
        <description>The PASI score measures the severity and extent of psoriasis. Using a scale of 0=none to 4= very severe, each body region (head, trunk, arms, and legs) is rated for redness, thickness, and scaling of the largest psoriatic area in that region producing a Lesion Score. The percentage of the area affected by disease is then estimated, ranging from 0 = no lesions to 6 = 90-100% of the region is covered providing an Area Score. Then, the Lesion Score and Area Score for each region are multiplied, producing 4 subtotals. The 4 region subtotals are multiplied by a standardized percentage of body surface area for that region (head = 0.1, trunk = 0.3, arms=0.2, and legs = 0.4); these four region calculations are added to provide the final PASI score, ranging from 0 = no disease to 72 = maximal disease). PASI 100 response was defined as 100 % improvement in PASI score when compared to the baseline score.</description>
        <time_frame>Week 16</time_frame>
        <population>The FAS, all randomized participants who received &gt;=1 dose of study drug and had a baseline and &gt;=1 post-treatment efficacy measurement, and data fior this endpoint</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Tildrakizumab 5 mg</title>
            <description>Participants receive tildrakizumab 5 mg, subcutaneously (SC) at Weeks 0 and 4</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Tildrakizumab 25 mg</title>
            <description>Participants receive tildrakizumab 25 mg, SC, at Weeks 0 and 4</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Tildrakizumab 100 mg</title>
            <description>Participants receive tildrakizumab 100 mg, SC, at Weeks 0 and 4</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Tildrakizumab 200 mg</title>
            <description>Participants receive tildrakizumab 200 mg, SC, at Weeks 0 and 4</description>
          </group>
          <group group_id="O5">
            <title>Part 1: Placebo</title>
            <description>Participants receive placebo, SC, at Weeks 0 and 4</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With PASI 100 Response at Week 16</title>
          <description>The PASI score measures the severity and extent of psoriasis. Using a scale of 0=none to 4= very severe, each body region (head, trunk, arms, and legs) is rated for redness, thickness, and scaling of the largest psoriatic area in that region producing a Lesion Score. The percentage of the area affected by disease is then estimated, ranging from 0 = no lesions to 6 = 90-100% of the region is covered providing an Area Score. Then, the Lesion Score and Area Score for each region are multiplied, producing 4 subtotals. The 4 region subtotals are multiplied by a standardized percentage of body surface area for that region (head = 0.1, trunk = 0.3, arms=0.2, and legs = 0.4); these four region calculations are added to provide the final PASI score, ranging from 0 = no disease to 72 = maximal disease). PASI 100 response was defined as 100 % improvement in PASI score when compared to the baseline score.</description>
          <population>The FAS, all randomized participants who received &gt;=1 dose of study drug and had a baseline and &gt;=1 post-treatment efficacy measurement, and data fior this endpoint</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="88"/>
                <count group_id="O4" value="84"/>
                <count group_id="O5" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0"/>
                    <measurement group_id="O2" value="9.20"/>
                    <measurement group_id="O3" value="14.77"/>
                    <measurement group_id="O4" value="16.67"/>
                    <measurement group_id="O5" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PASI 75 Response Rate by Time</title>
        <description>The PASI score measures the severity and extent of psoriasis. Using a scale of 0=none to 4= very severe, each body region (head, trunk, arms, and legs) is rated for redness, thickness, and scaling of the largest psoriatic area in that region producing a Lesion Score. The percentage of the area affected by disease is then estimated, ranging from 0 = no lesions to 6 = 90-100% of the region is covered providing an Area Score. Then, the Lesion Score and Area Score for each region are multiplied, producing 4 subtotals. The 4 region subtotals are multiplied by a standardized percentage of body surface area for that region (head = 0.1, trunk = 0.3, arms=0.2, and legs = 0.4); these four region calculations are added to provide the final PASI score, ranging from 0 = no disease to 72 = maximal disease).PASI 75 response was defined as &gt;=75% improvement in PASI score when compared to the baseline score at Week 2, 4, 6, 8, 12, or 16.</description>
        <time_frame>Up to 16 Weeks</time_frame>
        <population>The FAS, all randomized participants who received &gt;=1 dose of study drug and had a baseline and &gt;=1 post-treatment efficacy measurement. and data for the specific Week.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Tildrakizumab 5 mg</title>
            <description>Participants receive tildrakizumab 5 mg, subcutaneously (SC) at Weeks 0 and 4</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Tildrakizumab 25 mg</title>
            <description>Participants receive tildrakizumab 25 mg, SC, at Weeks 0 and 4</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Tildrakizumab 100 mg</title>
            <description>Participants receive tildrakizumab 100 mg, SC, at Weeks 0 and 4</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Tildrakizumab 200 mg</title>
            <description>Participants receive tildrakizumab 200 mg, SC, at Weeks 0 and 4</description>
          </group>
          <group group_id="O5">
            <title>Part 1: Placebo</title>
            <description>Participants receive placebo, SC, at Weeks 0 and 4</description>
          </group>
        </group_list>
        <measure>
          <title>PASI 75 Response Rate by Time</title>
          <description>The PASI score measures the severity and extent of psoriasis. Using a scale of 0=none to 4= very severe, each body region (head, trunk, arms, and legs) is rated for redness, thickness, and scaling of the largest psoriatic area in that region producing a Lesion Score. The percentage of the area affected by disease is then estimated, ranging from 0 = no lesions to 6 = 90-100% of the region is covered providing an Area Score. Then, the Lesion Score and Area Score for each region are multiplied, producing 4 subtotals. The 4 region subtotals are multiplied by a standardized percentage of body surface area for that region (head = 0.1, trunk = 0.3, arms=0.2, and legs = 0.4); these four region calculations are added to provide the final PASI score, ranging from 0 = no disease to 72 = maximal disease).PASI 75 response was defined as &gt;=75% improvement in PASI score when compared to the baseline score at Week 2, 4, 6, 8, 12, or 16.</description>
          <population>The FAS, all randomized participants who received &gt;=1 dose of study drug and had a baseline and &gt;=1 post-treatment efficacy measurement. and data for the specific Week.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="89"/>
                <count group_id="O4" value="86"/>
                <count group_id="O5" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (n=42, 89, 89, 85, 45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="1.12"/>
                    <measurement group_id="O3" value="1.12"/>
                    <measurement group_id="O4" value="0.00"/>
                    <measurement group_id="O5" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=42, 89, 89, 85, 45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="11.24"/>
                    <measurement group_id="O3" value="11.24"/>
                    <measurement group_id="O4" value="3.53"/>
                    <measurement group_id="O5" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=40, 86, 88, 84,44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.50"/>
                    <measurement group_id="O2" value="20.93"/>
                    <measurement group_id="O3" value="25.00"/>
                    <measurement group_id="O4" value="30.95"/>
                    <measurement group_id="O5" value="2.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=40, 88, 87, 83, 43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.50"/>
                    <measurement group_id="O2" value="35.23"/>
                    <measurement group_id="O3" value="47.13"/>
                    <measurement group_id="O4" value="61.45"/>
                    <measurement group_id="O5" value="4.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=40, 87, 88, 83, 42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.00"/>
                    <measurement group_id="O2" value="59.77"/>
                    <measurement group_id="O3" value="61.36"/>
                    <measurement group_id="O4" value="73.49"/>
                    <measurement group_id="O5" value="4.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=40, 87, 88, 84, 41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.00"/>
                    <measurement group_id="O2" value="65.52"/>
                    <measurement group_id="O3" value="67.05"/>
                    <measurement group_id="O4" value="76.19"/>
                    <measurement group_id="O5" value="4.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in PASI Score at Weeks 12 and 16</title>
        <description>The PASI score measures the severity and extent of psoriasis. Using a scale of 0=none to 4= very severe, each body region (head, trunk, arms, and legs) is rated for redness, thickness, and scaling of the largest psoriatic area in that region producing a Lesion Score. The percentage of the area affected by disease is then estimated, ranging from 0 = no lesions to 6 = 90-100% of the region is covered providing an Area Score. Then, the Lesion Score and Area Score for each region are multiplied, producing 4 subtotals. The 4 region subtotals are multiplied by a standardized percentage of body surface area for that region (head = 0.1, trunk = 0.3, arms=0.2, and legs = 0.4); these four region calculations are added to provide the final PASI score, ranging from 0 = no disease to 72 = maximal disease).</description>
        <time_frame>Baseline and Weeks 12 and 16</time_frame>
        <population>The FAS, all randomized participants who received &gt;=1 dose of study drug and had a baseline and &gt;=1 post-treatment efficacy measurement, and data for Week 12 and Week 16.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Tildrakizumab 5 mg</title>
            <description>Participants receive tildrakizumab 5 mg, subcutaneously (SC) at Weeks 0 and 4</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Tildrakizumab 25 mg</title>
            <description>Participants receive tildrakizumab 25 mg, SC, at Weeks 0 and 4</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Tildrakizumab 100 mg</title>
            <description>Participants receive tildrakizumab 100 mg, SC, at Weeks 0 and 4</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Tildrakizumab 200 mg</title>
            <description>Participants receive tildrakizumab 200 mg, SC, at Weeks 0 and 4</description>
          </group>
          <group group_id="O5">
            <title>Part 1: Placebo</title>
            <description>Participants receive placebo, SC, at Weeks 0 and 4</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in PASI Score at Weeks 12 and 16</title>
          <description>The PASI score measures the severity and extent of psoriasis. Using a scale of 0=none to 4= very severe, each body region (head, trunk, arms, and legs) is rated for redness, thickness, and scaling of the largest psoriatic area in that region producing a Lesion Score. The percentage of the area affected by disease is then estimated, ranging from 0 = no lesions to 6 = 90-100% of the region is covered providing an Area Score. Then, the Lesion Score and Area Score for each region are multiplied, producing 4 subtotals. The 4 region subtotals are multiplied by a standardized percentage of body surface area for that region (head = 0.1, trunk = 0.3, arms=0.2, and legs = 0.4); these four region calculations are added to provide the final PASI score, ranging from 0 = no disease to 72 = maximal disease).</description>
          <population>The FAS, all randomized participants who received &gt;=1 dose of study drug and had a baseline and &gt;=1 post-treatment efficacy measurement, and data for Week 12 and Week 16.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="89"/>
                <count group_id="O4" value="86"/>
                <count group_id="O5" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.2" lower_limit="-12.5" upper_limit="-7.9"/>
                    <measurement group_id="O2" value="-14.4" lower_limit="-16.0" upper_limit="-12.9"/>
                    <measurement group_id="O3" value="-14.1" lower_limit="-15.7" upper_limit="-12.5"/>
                    <measurement group_id="O4" value="-14.9" lower_limit="-16.5" upper_limit="-13.3"/>
                    <measurement group_id="O5" value="-2.2" lower_limit="-4.4" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.0" lower_limit="-12.3" upper_limit="-7.6"/>
                    <measurement group_id="O2" value="-14.6" lower_limit="-16.2" upper_limit="-13.0"/>
                    <measurement group_id="O3" value="-14.9" lower_limit="-16.5" upper_limit="-13.3"/>
                    <measurement group_id="O4" value="-15.6" lower_limit="-17.2" upper_limit="-14.0"/>
                    <measurement group_id="O5" value="-2.4" lower_limit="-4.7" upper_limit="-0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With PASI 50 Response at Week 16</title>
        <description>The PASI score measures the severity and extent of psoriasis. Using a scale of 0=none to 4= very severe, each body region (head, trunk, arms, and legs) is rated for redness, thickness, and scaling of the largest psoriatic area in that region producing a Lesion Score. The percentage of the area affected by disease is then estimated, ranging from 0 = no lesions to 6 = 90-100% of the region is covered providing an Area Score. Then, the Lesion Score and Area Score for each region are multiplied, producing 4 subtotals. The 4 region subtotals are multiplied by a standardized percentage of body surface area for that region (head = 0.1, trunk = 0.3, arms=0.2, and legs = 0.4); these four region calculations are added to provide the final PASI score, ranging from 0 = no disease to 72 = maximal disease). PASI 50 response was defined as &gt;=50 % improvement in PASI score when compared to the baseline score.</description>
        <time_frame>Week 16</time_frame>
        <population>The FAS, all randomized participants who received &gt;=1 dose of study drug and had a baseline and &gt;=1 post-treatment efficacy measurement. The last non-missing post-baseline PASI score was carried forward (LOCF) unless the participant discontinued drug due to lack of efficacy, loss of response, or use of prohibited medications.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Tildrakizumab 5 mg</title>
            <description>Participants receive tildrakizumab 5 mg, subcutaneously (SC) at Weeks 0 and 4</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Tildrakizumab 25 mg</title>
            <description>Participants receive tildrakizumab 25 mg, SC, at Weeks 0 and 4</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Tildrakizumab 100 mg</title>
            <description>Participants receive tildrakizumab 100 mg, SC, at Weeks 0 and 4</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Tildrakizumab 200 mg</title>
            <description>Participants receive tildrakizumab 200 mg, SC, at Weeks 0 and 4</description>
          </group>
          <group group_id="O5">
            <title>Part 1: Placebo</title>
            <description>Participants receive placebo, SC, at Weeks 0 and 4</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With PASI 50 Response at Week 16</title>
          <description>The PASI score measures the severity and extent of psoriasis. Using a scale of 0=none to 4= very severe, each body region (head, trunk, arms, and legs) is rated for redness, thickness, and scaling of the largest psoriatic area in that region producing a Lesion Score. The percentage of the area affected by disease is then estimated, ranging from 0 = no lesions to 6 = 90-100% of the region is covered providing an Area Score. Then, the Lesion Score and Area Score for each region are multiplied, producing 4 subtotals. The 4 region subtotals are multiplied by a standardized percentage of body surface area for that region (head = 0.1, trunk = 0.3, arms=0.2, and legs = 0.4); these four region calculations are added to provide the final PASI score, ranging from 0 = no disease to 72 = maximal disease). PASI 50 response was defined as &gt;=50 % improvement in PASI score when compared to the baseline score.</description>
          <population>The FAS, all randomized participants who received &gt;=1 dose of study drug and had a baseline and &gt;=1 post-treatment efficacy measurement. The last non-missing post-baseline PASI score was carried forward (LOCF) unless the participant discontinued drug due to lack of efficacy, loss of response, or use of prohibited medications.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="89"/>
                <count group_id="O4" value="86"/>
                <count group_id="O5" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.14"/>
                    <measurement group_id="O2" value="82.22"/>
                    <measurement group_id="O3" value="82.02"/>
                    <measurement group_id="O4" value="91.86"/>
                    <measurement group_id="O5" value="8.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 16</title>
        <description>The DLQI is a 10-item questionnaire that measures how much participant skin problems have affected their life. Responses range from 0=Not at all to 3=Very much. The DLQI is broken down into 6 subscales: Symptoms and feelings (range 0-6), Daily activities (range 0-6), Leisure (range 0-6), Work and school (range 0-3), Personal relationships (range 0-6), and Treatment (range 0-3). DLQI subscales were summed to yield the DLQI total score, which could range from 0 to 30. For both DLQI subscales and DLQI total score, a higher score indicated a greater negative impact on life.</description>
        <time_frame>Week 16</time_frame>
        <population>The FAS, all randomized participants who received &gt;=1 dose of study drug and had a baseline and &gt;=1 post-treatment efficacy measurement, and had data for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Tildrakizumab 5 mg</title>
            <description>Participants receive tildrakizumab 5 mg, subcutaneously (SC) at Weeks 0 and 4</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Tildrakizumab 25 mg</title>
            <description>Participants receive tildrakizumab 25 mg, SC, at Weeks 0 and 4</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Tildrakizumab 100 mg</title>
            <description>Participants receive tildrakizumab 100 mg, SC, at Weeks 0 and 4</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Tildrakizumab 200 mg</title>
            <description>Participants receive tildrakizumab 200 mg, SC, at Weeks 0 and 4</description>
          </group>
          <group group_id="O5">
            <title>Part 1: Placebo</title>
            <description>Participants receive placebo, SC, at Weeks 0 and 4</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 16</title>
          <description>The DLQI is a 10-item questionnaire that measures how much participant skin problems have affected their life. Responses range from 0=Not at all to 3=Very much. The DLQI is broken down into 6 subscales: Symptoms and feelings (range 0-6), Daily activities (range 0-6), Leisure (range 0-6), Work and school (range 0-3), Personal relationships (range 0-6), and Treatment (range 0-3). DLQI subscales were summed to yield the DLQI total score, which could range from 0 to 30. For both DLQI subscales and DLQI total score, a higher score indicated a greater negative impact on life.</description>
          <population>The FAS, all randomized participants who received &gt;=1 dose of study drug and had a baseline and &gt;=1 post-treatment efficacy measurement, and had data for this endpoint.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="88"/>
                <count group_id="O4" value="83"/>
                <count group_id="O5" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.9" lower_limit="-7.0" upper_limit="-2.8"/>
                    <measurement group_id="O2" value="-9.2" lower_limit="-10.6" upper_limit="-7.7"/>
                    <measurement group_id="O3" value="-8.5" lower_limit="-9.9" upper_limit="-7.1"/>
                    <measurement group_id="O4" value="-8.8" lower_limit="-10.3" upper_limit="-7.4"/>
                    <measurement group_id="O5" value="1.0" lower_limit="-1.1" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving DLQI Score of 0 or 1 at Week 16</title>
        <description>The DLQI is a 10-item questionnaire that measures how much participant skin problems have affected their life. Responses range from 0=Not at all to 3=Very much. The DLQI is broken down into 6 subscales: Symptoms and feelings (range 0-6), Daily activities (range 0-6), Leisure (range 0-6), Work and school (range 0-3), Personal relationships (range 0-6), and Treatment (range 0-3). DLQI subscales were summed to yield the DLQI total score, which could range from 0 to 30. For both DLQI subscales and DLQI total score, a higher score indicated a greater negative impact on life.</description>
        <time_frame>Week 16</time_frame>
        <population>The FAS, all randomized participants who received &gt;=1 dose of study drug and had a baseline and &gt;=1 post-treatment efficacy measurement, and data for this endpoint, excluding all participants on the placebo arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Tildrakizumab 5 mg</title>
            <description>Participants receive tildrakizumab 5 mg, subcutaneously (SC) at Weeks 0 and 4</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Tildrakizumab 25 mg</title>
            <description>Participants receive tildrakizumab 25 mg, SC, at Weeks 0 and 4</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Tildrakizumab 100 mg</title>
            <description>Participants receive tildrakizumab 100 mg, SC, at Weeks 0 and 4</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Tildrakizumab 200 mg</title>
            <description>Participants receive tildrakizumab 200 mg, SC, at Weeks 0 and 4</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving DLQI Score of 0 or 1 at Week 16</title>
          <description>The DLQI is a 10-item questionnaire that measures how much participant skin problems have affected their life. Responses range from 0=Not at all to 3=Very much. The DLQI is broken down into 6 subscales: Symptoms and feelings (range 0-6), Daily activities (range 0-6), Leisure (range 0-6), Work and school (range 0-3), Personal relationships (range 0-6), and Treatment (range 0-3). DLQI subscales were summed to yield the DLQI total score, which could range from 0 to 30. For both DLQI subscales and DLQI total score, a higher score indicated a greater negative impact on life.</description>
          <population>The FAS, all randomized participants who received &gt;=1 dose of study drug and had a baseline and &gt;=1 post-treatment efficacy measurement, and data for this endpoint, excluding all participants on the placebo arm.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="88"/>
                <count group_id="O4" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.5"/>
                    <measurement group_id="O2" value="57.47"/>
                    <measurement group_id="O3" value="52.27"/>
                    <measurement group_id="O4" value="57.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving a &gt;=5 Point Reduction in DLQI at Week 16</title>
        <description>The DLQI is a 10-item questionnaire that measures how much participant skin problems have affected their life. Responses range from 0=Not at all to 3=Very much. The DLQI is broken down into 6 subscales: Symptoms and feelings (range 0-6), Daily activities (range 0-6), Leisure (range 0-6), Work and school (range 0-3), Personal relationships (range 0-6), and Treatment (range 0-3). DLQI subscales were summed to yield the DLQI total score, which could range from 0 to 30. For both DLQI subscales and DLQI total score, a higher score indicated a greater negative impact on life.</description>
        <time_frame>Week 16</time_frame>
        <population>The FAS, all randomized participants who received &gt;=1 dose of study drug and had a baseline and &gt;=1 post-treatment efficacy measurement, and had data for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Tildrakizumab 5 mg</title>
            <description>Participants receive tildrakizumab 5 mg, subcutaneously (SC) at Weeks 0 and 4</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Tildrakizumab 25 mg</title>
            <description>Participants receive tildrakizumab 25 mg, SC, at Weeks 0 and 4</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Tildrakizumab 100 mg</title>
            <description>Participants receive tildrakizumab 100 mg, SC, at Weeks 0 and 4</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Tildrakizumab 200 mg</title>
            <description>Participants receive tildrakizumab 200 mg, SC, at Weeks 0 and 4</description>
          </group>
          <group group_id="O5">
            <title>Part 1: Placebo</title>
            <description>Participants receive placebo, SC, at Weeks 0 and 4</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a &gt;=5 Point Reduction in DLQI at Week 16</title>
          <description>The DLQI is a 10-item questionnaire that measures how much participant skin problems have affected their life. Responses range from 0=Not at all to 3=Very much. The DLQI is broken down into 6 subscales: Symptoms and feelings (range 0-6), Daily activities (range 0-6), Leisure (range 0-6), Work and school (range 0-3), Personal relationships (range 0-6), and Treatment (range 0-3). DLQI subscales were summed to yield the DLQI total score, which could range from 0 to 30. For both DLQI subscales and DLQI total score, a higher score indicated a greater negative impact on life.</description>
          <population>The FAS, all randomized participants who received &gt;=1 dose of study drug and had a baseline and &gt;=1 post-treatment efficacy measurement, and had data for this endpoint.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="88"/>
                <count group_id="O4" value="83"/>
                <count group_id="O5" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.50"/>
                    <measurement group_id="O2" value="70.11"/>
                    <measurement group_id="O3" value="64.77"/>
                    <measurement group_id="O4" value="73.49"/>
                    <measurement group_id="O5" value="19.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Experiencing Adverse Events</title>
        <description>An adverse event is any unfavorable and unintended change in the structure, function, or chemistry of the body whether or not considered related to the study treatment.</description>
        <time_frame>Up to 72 weeks</time_frame>
        <population>All participants receiving at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Tildrakizumab 5 mg</title>
            <description>Participants receive tildrakizumab 5 mg, subcutaneously (SC) at Weeks 0 and 4</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Tildrakizumab 25 mg</title>
            <description>Participants receive tildrakizumab 25 mg, SC, at Weeks 0 and 4</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Tildrakizumab 100 mg</title>
            <description>Participants receive tildrakizumab 100 mg, SC, at Weeks 0 and 4</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Tildrakizumab 200 mg</title>
            <description>Participants receive tildrakizumab 200 mg, SC, at Weeks 0 and 4</description>
          </group>
          <group group_id="O5">
            <title>Part 1: Placebo</title>
            <description>Participants receive placebo, SC, at Weeks 0 and 4</description>
          </group>
          <group group_id="O6">
            <title>Part 2: Tildrakizumab 5 mg</title>
            <description>Participants receive tildrakizumab 5 mg, SC, every 12 weeks for up to 36 weeks</description>
          </group>
          <group group_id="O7">
            <title>Part 2: Tildrakizumab 25 mg</title>
            <description>Participants receive tildrakizumab 25 mg, SC, every 12 weeks for up to 36 weeks</description>
          </group>
          <group group_id="O8">
            <title>Part 2: Tildrakizumab 100 mg</title>
            <description>Participants receive tildrakizumab 100 mg, SC, every 12 weeks for up to 36 weeks</description>
          </group>
          <group group_id="O9">
            <title>Part 2: Tildrakizumab 200 mg</title>
            <description>Participants receive tildrakizumab 200 mg, SC, every 12 weeks for up to 36 weeks</description>
          </group>
          <group group_id="O10">
            <title>Part 3: Tildrakizumab 5 mg Follow-up</title>
            <description>Participants are followed for up to 20 weeks after the last dose of study drug</description>
          </group>
          <group group_id="O11">
            <title>Part 3: Tildrakizumab 25 mg Follow-up</title>
            <description>Participants are followed for up to 20 weeks after the last dose of study drug</description>
          </group>
          <group group_id="O12">
            <title>Part 3: Tildrakizumab 100 mg Follow-up</title>
            <description>Participants are followed for up to 20 weeks after the last dose of study drug</description>
          </group>
          <group group_id="O13">
            <title>Part 3: Tildrakizumab 200 mg Follow-up</title>
            <description>Participants are followed for up to 20 weeks after the last dose of study drug</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Adverse Events</title>
          <description>An adverse event is any unfavorable and unintended change in the structure, function, or chemistry of the body whether or not considered related to the study treatment.</description>
          <population>All participants receiving at least one dose of study drug.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="91"/>
                <count group_id="O3" value="89"/>
                <count group_id="O4" value="86"/>
                <count group_id="O5" value="45"/>
                <count group_id="O6" value="13"/>
                <count group_id="O7" value="94"/>
                <count group_id="O8" value="153"/>
                <count group_id="O9" value="79"/>
                <count group_id="O10" value="10"/>
                <count group_id="O11" value="86"/>
                <count group_id="O12" value="126"/>
                <count group_id="O13" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="56"/>
                    <measurement group_id="O3" value="58"/>
                    <measurement group_id="O4" value="54"/>
                    <measurement group_id="O5" value="31"/>
                    <measurement group_id="O6" value="7"/>
                    <measurement group_id="O7" value="60"/>
                    <measurement group_id="O8" value="105"/>
                    <measurement group_id="O9" value="52"/>
                    <measurement group_id="O10" value="3"/>
                    <measurement group_id="O11" value="32"/>
                    <measurement group_id="O12" value="53"/>
                    <measurement group_id="O13" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Particpants Discontinuing Study Treatment Due to Adverse Events</title>
        <description>An adverse event is any unfavorable and unintended change in the structure, function, or chemistry of the body whether or not considered related to the study treatment. Participants may be discontinued from study drug due to adverse events, but remain on the study.</description>
        <time_frame>Up to 52 weeks</time_frame>
        <population>All particpants receiving at least one dose of study drug during the treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Tildrakizumab 5 mg</title>
            <description>Participants receive tildrakizumab 5 mg, subcutaneously (SC) at Weeks 0 and 4</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Tildrakizumab 25 mg</title>
            <description>Participants receive tildrakizumab 25 mg, SC, at Weeks 0 and 4</description>
          </group>
          <group group_id="O3">
            <title>Part 1: Tildrakizumab 100 mg</title>
            <description>Participants receive tildrakizumab 100 mg, SC, at Weeks 0 and 4</description>
          </group>
          <group group_id="O4">
            <title>Part 1: Tildrakizumab 200 mg</title>
            <description>Participants receive tildrakizumab 200 mg, SC, at Weeks 0 and 4</description>
          </group>
          <group group_id="O5">
            <title>Part 1: Placebo</title>
            <description>Participants receive placebo, SC, at Weeks 0 and 4</description>
          </group>
          <group group_id="O6">
            <title>Part 2: Tildrakizumab 5 mg</title>
            <description>Participants receive tildrakizumab 5 mg, SC, every 12 weeks for up to 36 weeks</description>
          </group>
          <group group_id="O7">
            <title>Part 2: Tildrakizumab 25 mg</title>
            <description>Participants receive tildrakizumab 25 mg, SC, every 12 weeks for up to 36 weeks</description>
          </group>
          <group group_id="O8">
            <title>Part 2: Tildrakizumab 100 mg</title>
            <description>Participants receive tildrakizumab 100 mg, SC, every 12 weeks for up to 36 weeks</description>
          </group>
          <group group_id="O9">
            <title>Part 2: Tildrakizumab 200 mg</title>
            <description>Participants receive tildrakizumab 200 mg, SC, every 12 weeks for up to 36 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Particpants Discontinuing Study Treatment Due to Adverse Events</title>
          <description>An adverse event is any unfavorable and unintended change in the structure, function, or chemistry of the body whether or not considered related to the study treatment. Participants may be discontinued from study drug due to adverse events, but remain on the study.</description>
          <population>All particpants receiving at least one dose of study drug during the treatment period.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="91"/>
                <count group_id="O3" value="89"/>
                <count group_id="O4" value="86"/>
                <count group_id="O5" value="45"/>
                <count group_id="O6" value="13"/>
                <count group_id="O7" value="94"/>
                <count group_id="O8" value="153"/>
                <count group_id="O9" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="5"/>
                    <measurement group_id="O9" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 72 weeks</time_frame>
      <desc>All participants who received at least one dose of tildrakizumab or placebo.</desc>
      <group_list>
        <group group_id="E1">
          <title>Part 1: Tildrakizumab 5 mg</title>
          <description>Participants receive tildrakizumab 5 mg, subcutaneously (SC) at Weeks 0 and 4</description>
        </group>
        <group group_id="E2">
          <title>Part 1: Tildrakizumab 25 mg</title>
          <description>Participants receive tildrakizumab 25 mg, SC, at Weeks 0 and 4</description>
        </group>
        <group group_id="E3">
          <title>Part 1: Tildrakizumab 100 mg</title>
          <description>Participants receive tildrakizumab 100 mg, SC, at Weeks 0 and 4</description>
        </group>
        <group group_id="E4">
          <title>Part 1: Tildrakizumab 200 mg</title>
          <description>Participants receive tildrakizumab 200 mg, SC, at Weeks 0 and 4</description>
        </group>
        <group group_id="E5">
          <title>Part 1: Placebo</title>
          <description>Participants receive placebo, SC, at Weeks 0 and 4</description>
        </group>
        <group group_id="E6">
          <title>Part 2: Tildrakizumab 5 mg</title>
          <description>Participants receive tildrakizumab 5 mg, SC, every 12 weeks for up to 36 weeks</description>
        </group>
        <group group_id="E7">
          <title>Part 2: Tildrakizumab 25 mg</title>
          <description>Participants receive tildrakizumab 25 mg, SC, every 12 weeks for up to 36 weeks</description>
        </group>
        <group group_id="E8">
          <title>Part 2: Tildrakizumab 100 mg</title>
          <description>Participants receive tildrakizumab 100 mg, SC, every 12 weeks for up to 36 weeks</description>
        </group>
        <group group_id="E9">
          <title>Part 2: Tildrakizumab 200 mg</title>
          <description>Participants receive tildrakizumab 200 mg, SC, every 12 weeks for up to 36 weeks</description>
        </group>
        <group group_id="E10">
          <title>Part 3: Tildrakizumab 5 mg Follow-up</title>
          <description>Participants are followed for up to 20 weeks after the last dose of study drug.</description>
        </group>
        <group group_id="E11">
          <title>Part 3: Tildrakizumab 25 mg Follow-up</title>
          <description>Participants are followed for up to 20 weeks after the last dose of study drug.</description>
        </group>
        <group group_id="E12">
          <title>Part 3: Tildrakizumab 100 mg Follow-up</title>
          <description>Participants are followed for up to 20 weeks after the last dose of study drug.</description>
        </group>
        <group group_id="E13">
          <title>Part 3: Tildrakizumab 200 mg Follow-up</title>
          <description>Participants are followed for up to 20 weeks after the last dose of study drug.</description>
        </group>
        <group group_id="E14">
          <title>Placebo Follow-up</title>
          <description>Participants who received placebo in Part 1 and did not receive additional therapy.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="94"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="153"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Epiglottitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E8" events="2" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Tendonn rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Psoriatic arthropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Malignant melanoma in situ</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E8" events="2" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Thrombotic cerebral infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="91"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="30" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="38" subjects_at_risk="94"/>
                <counts group_id="E8" subjects_affected="64" subjects_at_risk="153"/>
                <counts group_id="E9" subjects_affected="32" subjects_at_risk="79"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E11" subjects_affected="14" subjects_at_risk="87"/>
                <counts group_id="E12" subjects_affected="29" subjects_at_risk="137"/>
                <counts group_id="E13" subjects_affected="17" subjects_at_risk="75"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Odontogenic cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="91"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="89"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="86"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E8" events="6" subjects_affected="5" subjects_at_risk="153"/>
                <counts group_id="E9" events="4" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E8" events="4" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute tonsilitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Bronchiitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="91"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E8" events="6" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E9" events="3" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E4" events="4" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="89"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="86"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E7" events="5" subjects_affected="5" subjects_at_risk="94"/>
                <counts group_id="E8" events="5" subjects_affected="4" subjects_at_risk="153"/>
                <counts group_id="E9" events="5" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="42"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="91"/>
                <counts group_id="E3" events="15" subjects_affected="13" subjects_at_risk="89"/>
                <counts group_id="E4" events="11" subjects_affected="11" subjects_at_risk="86"/>
                <counts group_id="E5" events="10" subjects_affected="9" subjects_at_risk="45"/>
                <counts group_id="E6" events="4" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E7" events="32" subjects_affected="24" subjects_at_risk="94"/>
                <counts group_id="E8" events="42" subjects_affected="34" subjects_at_risk="153"/>
                <counts group_id="E9" events="21" subjects_affected="13" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" events="9" subjects_affected="6" subjects_at_risk="87"/>
                <counts group_id="E12" events="13" subjects_affected="12" subjects_at_risk="137"/>
                <counts group_id="E13" events="6" subjects_affected="5" subjects_at_risk="75"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="89"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="5" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E8" events="7" subjects_affected="6" subjects_at_risk="153"/>
                <counts group_id="E9" events="5" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E12" events="3" subjects_affected="3" subjects_at_risk="137"/>
                <counts group_id="E13" events="3" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="91"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure systolic increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="91"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="89"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="86"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="5" subjects_affected="4" subjects_at_risk="94"/>
                <counts group_id="E8" events="8" subjects_affected="8" subjects_at_risk="153"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E11" events="4" subjects_affected="3" subjects_at_risk="87"/>
                <counts group_id="E12" events="5" subjects_affected="5" subjects_at_risk="137"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E2" events="8" subjects_affected="5" subjects_at_risk="91"/>
                <counts group_id="E3" events="8" subjects_affected="6" subjects_at_risk="89"/>
                <counts group_id="E4" events="8" subjects_affected="7" subjects_at_risk="86"/>
                <counts group_id="E5" events="6" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E8" events="17" subjects_affected="13" subjects_at_risk="153"/>
                <counts group_id="E9" events="6" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E12" events="7" subjects_affected="5" subjects_at_risk="137"/>
                <counts group_id="E13" events="3" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="91"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E8" events="5" subjects_affected="5" subjects_at_risk="153"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E8" events="3" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="91"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E4" events="6" subjects_affected="4" subjects_at_risk="86"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Investigator agrees not to publish or publicly present any interim results of the trial without the prior written consent of the Sponsor. The investigator further agrees to provide to the Sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication in any media that report any results of the trial. The Sponsor shall have the right to review and comment on the data analysis and presentation.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

